<DOC>
	<DOCNO>NCT01834222</DOCNO>
	<brief_summary>The purpose study assess safety profile Prevenar 13™ use among Korean adult routine clinical setting , require new drug approve Korea Food Drug Administration ( KFDA ) .</brief_summary>
	<brief_title>Post Market Surveillance Observe Safety Prevenar13™ Adults</brief_title>
	<detailed_description>non-randomization , non-probability sampling</detailed_description>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Korean adult age 18 year old ; provide condition pertain contraindication , warning , precaution , interaction state local product document apply . Evidence personally sign date informed consent document indicate subject ( legally acceptable representative ) inform pertinent aspect study . Subjects indicate and/or contraindicate Prevenar13 usage include .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>